智通财经APP获悉，香港联交所最新资料显示，8月5日，陈妙龄增持紫元元(08223)2732万股，每股作价 1.38港元，总金额为3770.16万港元。增持后最新持股数目约为2732万股，最新持股比例为6.35%。 ...

Group 1 - The company announced the resignation of Mr. Huang Guoxin as the co-secretary and authorized representative effective from August 20, 2025 [1] - Ms. Li Xinpei will continue as the company secretary and has been appointed as the authorized representative and legal document agent effective from August 20, 2025 [1] - Following the changes, the authorized representatives will be Mr. Zhang Junshen and Ms. Li Xinpei [1]

黃先生已確認，其與董事會並無意見分歧，且概無有關其辭任之事宜須提請本公司股東或聯交所 垂注。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該 等內容而引致的任何損失承擔任何責任。 Ziyuanyuan Holdings Group Limited 紫元元控股集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：8223） 公司秘書之辭任 及 授權代表及 法律程序文件代理人之變更 紫元元控股集團有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此公佈， 黃國新 先生（「黃先生」）已辭任本公司聯席公司秘書（「公司秘書」）、香港聯合交易所有限公司 （「聯交所」）GEM 證券上市規則（「GEM 上市規則」）第 5.24 條項下的本公司授權代表（「授 權代表」）及根據公司條例（香港法例第 622 章）第 16 部及 GEM 上市規則第 24.05(2)條規定代 表本公司於香港接收法律程序文件或通知本公司之授權代表（「法律程序文件代理人」），自二 零二五年八月二十日起生效。 於本公告日期 ...

紫元元控股集團有限公司（「本公司」）董事（「董事」）會（「董事會」）茲通告本公司將於 二零二五年八月二十九日(星期五)於中國深圳市南山區大新路 198 號馬家龍創新大廈 A 座 10 層舉 行董事會會議，以(其中包括)考慮及批准本公司及其附屬公司截至二零二五年六月三十日止六個 月的中期業績公告及建議派發中期股息(如有)。 承董事會命 紫元元控股集團有限公司 主席兼行政總裁 張俊深先生 香港，二零二五年八月十五日 於本公告日期，執行董事為張俊深先生（主席兼行政總裁）及田志威先生，非執行董事為呂迪先 生及李新培女士，而獨立非執行董事為陳志峰先生、周兆恒先生及鄧斌博士。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該 等內容而引致的任何損失承擔任何責任。 Ziyuanyuan Holdings Group Limited 紫元元控股集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：8223） 董事會會議召開日期 本公告將由刊登日期起計最少七天於披露易網站www.hkexnews.hk ...

此前紫元元发布2024年度业绩，总收益5.52亿元(人民币，下同)，同比增长10.9%;公司拥有人应占亏损 5297万元，上年同期溢利1456.3万元;每股基本亏损12.34分。 香港联交所最新资料显示，8月7日，紫元元(08223)股东将股票由粤商国际证券转入光大证券投资服务 香港，转仓市值2915.67万港元，占比6.71%。 ...

智通财经APP获悉，香港联交所最新资料显示，8月7日，紫元元(08223)股东将股票由粤商国际证券转入 光大证券投资服务香港，转仓市值2915.67万港元，占比6.71%。 此前紫元元发布2024年度业绩，总收益5.52亿元(人民币，下同)，同比增长10.9%;公司拥有人应占亏损 5297万元，上年同期溢利1456.3万元;每股基本亏损12.34分。 ...

8月4日，截至港股收盘，恒生指数上涨0.92%，报24733.45点。紫元元（08223.HK）收报0.94港元/股， 上涨16.05%，成交量534.4万股，成交额435.84万港元，振幅33.33%。 最近一个月来，紫元元累计跌幅47.4%，今年来累计跌幅49.06%，跑输恒生指数22.17%的涨幅。 行业估值方面，医疗保健设备和服务行业市盈率（TTM）平均值为-0.98倍，行业中值1.38倍。紫元元市 盈率-6.09倍，行业排名第86位；其他京玖康疗（00648.HK）为0.38倍、巨星医疗控股（02393.HK）为 0.41倍、医汇集团（08161.HK）为2.35倍、瑞慈医疗（01526.HK）为5.3倍、环球医疗（02666.HK）为 5.47倍。 资料显示，紫元元控股集团有限公司,香港联合交易所上市企业(股票代码:08223.HK),总部坐落于中国深 圳,分别在北京、杭州、武汉、河南、成都、广州、香港等地设有办事处。 财务数据显示，截至2024年12月31日，紫元元实现营业总收入5.52亿元，同比增长10.91%；归母净利 润-5297万元，同比减少463.73%；毛利率15.67%，资产负债率 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 紫元元控股集團有限公司 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08223 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | 0.1 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 1,000,000,000 | HKD | | 0.1 | HKD | | 100,000,000 | 本月底法定/註冊股 ...

资料显示，紫元元控股集团有限公司,香港联合交易所上市企业(股票代码:08223.HK),总部坐落于中国深 圳,分别在北京、杭州、武汉、河南、成都、广州、香港等地设有办事处。 6月16日，截至港股收盘，恒生指数上涨0.7%，报24060.99点。紫元元（08223.HK）收报1.7港元/股， 上涨14.09%，成交量179.8万股，成交额295.3万港元，振幅18.12%。 最近一个月来，紫元元累计跌幅5.7%，今年来累计跌幅6.29%，跑输恒生指数19.11%的涨幅。 财务数据显示，截至2024年12月31日，紫元元实现营业总收入5.52亿元，同比增长10.91%；归母净利 润-5297万元，同比减少463.73%；毛利率15.67%，资产负债率49.94%。 机构评级方面，目前暂无机构对该股做出投资评级建议。 行业估值方面，医疗保健设备和服务行业市盈率（TTM）平均值为-22.06倍，行业中值0.39倍。紫元元 市盈率-11.2倍，行业排名第74位；其他京玖康疗（00648.HK）为0.38倍、巨星医疗控股（02393.HK） 为0.4倍、永胜医疗（01612.HK）为4.39倍、环球医疗（02666.HK ...

Impairment and Financial Losses - The company recognized goodwill and intangible asset impairments of approximately RMB 9.9 million and RMB 8.5 million related to the acquisition of Dun Nan Group and Mei Kang Mao respectively[4]. - The estimated recoverable amount of Dun Nan's cash-generating unit was determined to be zero, resulting in a full impairment of RMB 9,885,000 in goodwill and RMB 8,500,000 in trademarks[8]. - Meikangmao's cash-generating unit has been written down to a recoverable amount of RMB 17,600,000, with a goodwill impairment loss of RMB 7,067,000 recognized[19]. - The impairment of finance lease receivables for the year ending December 31, 2024, is approximately RMB 35.6 million, accounting for about 5.9% of total assets[25]. Operational Challenges - The decision to cease operations of Dun Nan Group was made due to continuous operational losses since 2023, with a challenging macroeconomic environment leading to reduced consumer spending and increased competition[7]. - The overall economic environment in China remains challenging, impacting consumer spending and leading to ongoing losses for Meikangmao since its opening[17]. - The industry faces specific pressures, including reduced patient flow and increased competition, leading to cash flow difficulties for many clients[27]. - The macroeconomic environment in China is recovering slower than expected, impacting consumer confidence and increasing credit risk[28]. Future Projections and Strategies - Revenue and net loss forecasts for Dun Nan for the two months ending February 2025 are projected to be RMB 2,292,000 and RMB (3,920,000) respectively[11]. - The company plans to reallocate resources from Dun Nan Group to more sustainable and profitable business segments[7]. - The number of maternity centers is projected to increase by approximately 27% from 2021 to 2024, driven by China's three-child policy[15]. - The market for maternity services is highly competitive, with a compound annual growth rate of about 18% from 2016 to 2023, leading to an estimated 5,800 centers by 2024[17]. - The company believes that the healthcare industry will present growth opportunities post-pandemic, despite the challenges faced by Dun Nan Group[6]. Valuation and Financial Assessment - The company applied a 20.4% liquidity discount based on a study covering 779 private transactions from July 1980 to March 2024, reflecting the average discount rate for illiquid private equity[10]. - The weighted average cost of capital was calculated to be approximately 15%, based on comparable companies' average debt and equity ratios[12]. - The recoverable amount of cash-generating units is calculated based on the net present value of expected future cash flows over a 7-year period[23]. - The after-tax discount rate is approximately 15%, derived from the weighted average cost of capital based on comparable companies[23]. - The only applicable valuation multiple is the price-to-sales ratio, which is adopted as the basis for Meikangmao's equity value[22]. Operational Adjustments and Partnerships - The operational plan for Meikangmao was revised to include a partnership with an experienced operator, resulting in a fundamental change in the original business model[18]. - The company has actively engaged with two well-known maternity service providers to mitigate operational risks and costs[18]. Debt Recovery Efforts - The company has implemented a bad debt recovery policy, utilizing phone collections and legal actions as necessary[29]. - As of March 31, 2025, approximately 43% of overdue financing lease receivables cases have entered litigation or arbitration procedures[30]. - About 50% of these cases (by amount) have received court judgments in favor of the company, while the rest are still pending judgment[30]. - The company has successfully obtained court freezing orders on approximately 20.3% of the relevant financing lease receivables[30]. - The company has successfully recovered about 2.7% of the impairment amount of financing lease receivables as of March 31, 2025[30].